RVMD:NASDAQRevolution Medicines, Inc. Analysis

Revolution Medicines (RVMD) has surged to $144.83, comfortably above its 20‑day ($124.64), 50‑day ($109.19) and 200‑day ($74.79) simple moving averages, signaling strong momentum. Technical indicators reinforce this bullish bias: the RSI sits at 66.9 (near‑term overbought but still rising), the MACD line (10.90) exceeds its signal (10.64) with a positive histogram, and trading volume is on an increasing trend. The stock trades near its 52‑week high of $155.70, with clear support at $94 and upside potential of roughly 20% toward the median analyst target of $173. Recent news highlights a successful Phase 3 trial of daraxonrasib, driving a 41% one‑day rally and contributing to an “Extreme Greed” sentiment (Fear‑Greed Index 89.6). Despite a cash pile of $2.0 bn, the company remains loss‑making with negative EBITDA and free cash flow, high price‑to‑book (17.5×) and no dividend, underscoring reliance on future clinical milestones.